Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 8:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 970 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Drug A (Blinded Drug) Clear all
Completed Phase 4 Interventional Results available

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT04908475
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab, Apremilast
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
26
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 10, 2026, 8:33 AM EDT
Completed Not applicable Interventional Results available

A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement

NCT00756236
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Metoprolol, Esmolol, P-Group
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 10, 2026, 8:33 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

NCT00900731
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol, Placebo to tiotropium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 10, 2026, 8:33 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

NCT03547908
View directory record Official record
Conditions
HIV-1/HBV Co-Infection
Interventions
B/F/TAF, Placebo to match DTG, Placebo to match F/TDF, DTG, F/TDF, Placebo to match B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Berkley, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 10, 2026, 8:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

NCT04187560
View directory record Official record
Conditions
Schizophrenia
Interventions
LB-102
Drug
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 10, 2026, 8:33 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia

NCT00850993
View directory record Official record
Conditions
Hyperbilirubinemia, Neonatal
Interventions
Stannsoporfin, Placebo, PhotoTherapy (as needed)
Drug · Other
Lead sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Industry
Eligibility
1 Minute to 48 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Colton, California • San Diego, California • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 10, 2026, 8:33 AM EDT
Completed Phase 3 Interventional Results available

Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis

NCT02022007
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Disorder of Glucose Regulation
Interventions
Metformin XR, Saxagliptin, Saxagliptin-Metformin XR
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 10, 2026, 8:33 AM EDT
Recruiting Not applicable Interventional

Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients

NCT03245411
View directory record Official record
Conditions
Cancer
Interventions
Intervention
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 10, 2026, 8:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Brentuximab Vedotin for Systemic Sclerosis

NCT03222492
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
Interventions
Brentuximab Vedotin, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 10, 2026, 8:33 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

NCT05846399
View directory record Official record
Conditions
Cat Bite, Hand Injuries, Arm Injury, Infection, Bacterial, Anti-bacterial Agents
Interventions
Amoxicillin/clavulanate, Ciprofloxacin, Clindamycin, Placebo (microcrystalline cellulose), Wound management
Drug · Other · Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 10, 2026, 8:33 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

NCT01530763
View directory record Official record
Conditions
Infections, Community Acquired Pneumonia
Interventions
Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Oct 10, 2026, 8:33 AM EDT
Completed Phase 3 Interventional Results available

A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis

NCT01048866
View directory record Official record
Conditions
Pharyngitis
Interventions
placebo, flurbiprofen, acetaminophen 650mg
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 10, 2026, 8:33 AM EDT
Recruiting Phase 2 Interventional

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

NCT07246863
View directory record Official record
Conditions
Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Interventions
Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
Biological · Other · Drug
Lead sponsor
CatalYm GmbH
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 10, 2026, 8:33 AM EDT
Completed No phase listed Observational Results available

A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block

NCT02151487
View directory record Official record
Conditions
Upper Extremity Surgery
Interventions
Ropivacaine, Ropivacaine and dexamethasone, Ropivacaine and clonidine, Ropivacaine, dexamethasone and clonidine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 10, 2026, 8:33 AM EDT
Withdrawn Phase 2 Interventional

Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma

NCT01304628
View directory record Official record
Conditions
Asthma
Interventions
PL-3994
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cranbury, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Oct 10, 2026, 8:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound

NCT07304024
View directory record Official record
Conditions
Central Auditory Processing Disorder, Hearing Impaired (Partially), Hearing, Hearing Abnormality, Hearing Disability, Hearing Disorder, Hearing Disorders, Hearing Impairment, Sensorineural, Hearing Handicap, Hearing Impaired, Hearing Impairment, Hearing Loss, Central Auditory Disease, Noise Exposure, Noise Induced Hearing Loss, Noise-Induced Hearing Loss, Sound Perception, Myelin Degeneration, Myelinopathy, Myelin Integrity, Remyelination, Hidden Hearing Loss, Cocktail Party Skill, Cocktail Party Syndrome, CAPD, Age Problem
Interventions
Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound, Placebo - Placebo
Combination Product · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 10, 2026, 8:33 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

NCT07560150
View directory record Official record
Conditions
Pharmacokinetics, Pharmacodynamics, Insulin Aspart
Interventions
I004, NovoLog
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 10, 2026, 8:33 AM EDT
Recruiting Phase 4 Interventional

Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants

NCT06871488
View directory record Official record
Conditions
ADHD - Attention Deficit Disorder With Hyperactivity, Irritability, Aggression Childhood
Interventions
CNS Stimulant, Placebo, CNS Stimulant open label first phase
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
7 Years to 12 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 10, 2026, 8:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects

NCT03310359
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Astaxanthin, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 10, 2026, 8:33 AM EDT
Completed Phase 4 Interventional Results available

Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM

NCT03608774
View directory record Official record
Conditions
Anal Chlamydia Infection
Interventions
Azithromycin, Doxycycline, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 10, 2026, 8:33 AM EDT
Completed Phase 3 Interventional Results available

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

NCT04055090
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Interventions
Long-Term Follow-Up of Patients who Received Engensis (VM202), Long-Term Follow-Up of Patients who Received Placebo
Genetic · Drug
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 10, 2026, 8:33 AM EDT
Not yet recruiting Phase 4 Interventional

Discontinuation of Low-Dose Levothyroxine in Older Adults With Subclinical Hypothyroidism

NCT07787585
View directory record Official record
Conditions
Hypothyroidism
Interventions
Levothyroxine Pill, Placebo
Drug
Lead sponsor
Spyridoula Maraka
Other
Eligibility
65 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
3
States / cities
Little Rock, Arkansas • Gainesville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 10, 2026, 8:33 AM EDT
Withdrawn Not applicable Interventional

Antibiotic Therapy After Incision and Drainage for Abscess

NCT00900510
View directory record Official record
Conditions
Abscess
Interventions
Incision and drainage, Trimethoprim/Sulfamethoxazole (Bactrim), Placebo
Procedure · Drug
Lead sponsor
Wake Forest University
Other
Eligibility
6 Months to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 10, 2026, 8:33 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)

NCT00621478
View directory record Official record
Conditions
Status Epilepticus
Interventions
lorazepam or diazepam
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Months to 18 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
12
States / cities
Davis, California • Aurora, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 10, 2026, 8:33 AM EDT